Commercial ExecutionThe equally hard part now comes: commercial execution on the launch, and driving revenue, where the opportunity is somewhat limited.
Investor SentimentADAP shares are now trading down 10% intra-day, reflecting negative investor sentiment related to the headline news.
Strategic CollaborationThe strategic collaboration with Genentech to develop an allogeneic cell therapy program has been terminated.